Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7225632 | 0.90 | KMT2A (0.52) | SMN1; SMN2LMNAMAPTPTGDR2MEN1 | |
| SCHEMBL6474125 | 0.90 | PTGDR2 (0.64) | LMNAPTGDR2MEN1KMT2AKDM4E | |
| SCHEMBL6531341 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAMAPTPTGDR2MEN1 | |
| SCHEMBL6481086 | 0.86 | KDM4E (0.47) | SMN1; SMN2LMNAMAPTPTGDR2MEN1 | |
| Hydrochloric Acid SCHEMBL6482029 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAMAPTMEN1KMT2A | |
| SCHEMBL7220006 | 0.82 | MAPT (0.54) | MAPTPTGDR2MEN1KMT2AKDM4E | |
| SCHEMBL6475986 | 0.82 | KDM4E (0.47) | SMN1; SMN2MAPTMEN1KMT2AKDM4E | |
| SCHEMBL6474119 | 0.80 | PTGDR2 (0.56) | MAPTPTGDR2MEN1KMT2AKDM4E | |
| SCHEMBL7220867 | 0.79 | MAPT (0.53) | LMNAMAPTPTGDR2MEN1KMT2A | |
| SCHEMBL6475604 | 0.79 | HDAC1 (0.49) | SMN1; SMN2LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583135-B2 | Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | PHARMACIA & UPJOHN COMPANY | 2003-06-24 | — | — | US | disclosed |